Aug 4, 2017
Most readers know that I “graduated” from joint replacement surgery into an emerging field of Regenerative Medicine about five years ago. Prior to that time, I had dedicated 37 years to Reconstructive Orthopedic Surgery and played an active role in a joint replacement practice combining research with education as I improved the quality of life for my patients. By the end of my surgical career, I had authored more than 90 scientific papers in the field of hip and knee replacement as well serving in the leadership of the joint replacement program at a major medical center in Chicago.
That was “back in the day” of joint replacement surgery; but rather than live in the past, I have elected to partake in the present and advance Cellular Orthopedics into the future. I now have the largest and most comprehensive clinical outcomes data base in the United States concerning Bone Marrow Concentrate, Mechanical preparation of Adipose Graft, and Amniotic Fluid injection used in the treatment of knee arthritis. This information has allowed me, up until now, to make a scientifically based recommendation as to the best regenerative option for dealing with an arthritic joint.
In my initiative to advance the discipline of Cellular Orthopedics, the next innovation will be to offer a prior analysis of the stem cell content for the patient seeking the regenerative option as a means of postponing or avoiding a joint replacement. Should a patient present with osteoarthritis seeking to determine if she, he or hir will benefit from Adult Mesenchymal Stem Cells and Growth Factors, I am able to offer the equivalent of a bone marrow biopsy and determine the amount of viable cellular orthopedic content available in that individual’s bone marrow. My recommendations then would be based on actual number of cells and not on age related or disease influenced averages or estimates. Predictability of an individual’s outcome in determining whether to proceed with the regenerative intervention would be customized and not generalized. Where this scientific leap forward would be of particular interest includes patients over age 70, those who have received immune altering systemic management for a co-morbidity or for patients whose medication requirements up until now would have eliminated them from a regenerative consideration.
To learn more schedule an appointment 847 390 7666
You may access my web site and watch my Webinar at www.Ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, cellular orthopedics, Orthopedic Surgeon, Osteoarthritis, regenerative medicine, stem cell treatment
Jun 26, 2017
Five years ago, I “graduated” from a 37-year career as an orthopedic surgeon with a practice based on hip and knee replacement surgery for arthritic joints. Trading my scalpel for a needle, I entered the new discipline of Cellular Orthopedics with a goal of helping patients delay, at times avoid a joint replacement for the arthritic hip and knee joint. In my transition, I introduced the same integration of research, patient care, and education into Regenerative Medicine that I had pioneered as the head of a joint replacement program at a major-medical center in Chicago, helping that center emerge as one of the five most recognized programs in The United States.
At the beginning and continuing to this day, Cellular Orthopedics has been based on the use of a patient’s own Platelet Rich Plasma and Bone Marrow Concentrate as the source for providing pain relief and functional improvement to a patient experiencing impairment from an arthritic joint. I have almost five years of outcomes data to support my therapeutic recommendations. Platelet Rich Plasma offers healing and pain relieving promise for the patient; while the Stem Cells and Growth Factors in Bone Marrow Concentrate offer regenerative potential in addition, all this while FDA compliant.
Over the past year however, there has been an explosion in the marketing of untested and unproven alternatives continually introduced under the Regenerative Medicine umbrella. Web sites make unsubstantiated claims, purchased media campaigns become a source of false advertising and courses both live and on-line promise expertise credentialing in 48 hours.
As a response to this chaos, I have founded The Center for Orthobiologic Clinical Trials whereby I am able to validate or challenge the plethora of claims and assist my patients in decision making based on scientific evidence; while at the same time, contributing to the emerging discipline of Interventional Orthopedics. I now have gathered the largest Data Base with long term follow-up of which I am aware documenting the Outcomes of Bone Marrow Concentrate, Amniotic Fluid Concentrate and mechanically emulsified, Adipose Derived, Lipogems.
The next step is to study the outcomes of combining cellular orthopedic interventions into the joint with the added step of injecting Bone Marrow Concentrate and Platelet Rich Plasma into the bone adjacent to the joint. I am currently recruiting patients for the latter trial. For those who meet inclusion criteria, there is a discount for said care. Interested patients should call (312) 475-1893 on Monday or Thursday.
If you want to become better informed, browse my website www.sheinkopmd.com.
You may watch my webinar at www.ilcellulartherapy.com or call central schedulaing at (312) 475-1893 for a new patient consultation.
Tags: Amniotic Fluid Concentrate, Bone Marrow Concentrate, cellular treatment, Hip pain, joint replacement, knee pain, lipogems, mechanically emulsified Adipose Derived, Mesenchymal Stem Cell, Osteoarthritis, PRP, regenerative medicine
Jun 12, 2017
The lack of scientific foundation in stem cell marketing is all around us and negatively impacting those doing the right thing in the evolving discipline of Regenerative Medicine. Yesterday afternoon, a patient for whom I successfully completed a Bone Marrow Concentrate/Stem cell procedure presented to the office for a follow-up visit. She was accompanied by her husband who was experiencing progressive limitation attributable to an arthritic left knee. Because of my patient’s successful experience, her husband had determined now it was his turn. After the intake, I provided the customary explanation of what was to take place. During the question and answer follow-up, both husband, the new patient, and wife, the successful outcome, wanted to know why hers had worked whereas several of their friends had not enjoyed successful outcomes after amniotic fluid interventions.
The explanation is straightforward and based on a precedent, the fact speaks for itself. While Bone Marrow is full of Adult Mesenchymal Stem Cells and Growth Factors when harvested, processed, concentrated and reinjected into the symptomatic joint within 60 to 90 minutes after the harvesting; Amniotic Fluid has no living stem cells after sterilizing, freezing and fast thawing. Restated, Amniotic Fluid has little if any regenerative potential. Why am I able to make said statements in the face of such aggressive marketing claims regarding amniotic fluid? In addition to my work clinically and scientifically with Bone Marrow Derived stem cells and growth factors, I am the Principal Investigator in a clinical trial wherein amniotic fluid both frozen and fast thawed, and most recently, Lyophilized, has been used in lieu of hyaluronic acid to reduce or possible relieve the symptoms of osteoarthritis for six to 12 months. At no time did the largest amniotic product based pharmaceutical company in the United States suggest there are viable stem cells in amniotic fluid nor did they make any claim for regenerative potential. Returning to my office encounter, during our continued discussion, I learned that those who had opted for the amniotic fluid injection had paid more for the injections than I charge for the Bone Marrow intervention. So, think about the harm done to the “victims” as well as the public in general. The trusting patients paid for a regenerative procedure that they never received. The patients believing that the stem cell procedure didn’t work are now considering total joint replacements.
How might you protect yourself if you are considering a means by which you might postpone or avoid a joint replacement for arthritis? Make sure you choose a residency and fellowship trained interventional specialist. Second, ask the clinician to share his or her scientific outcomes data.
If you want to become better informed, browse my website www.sheinkopmd.com.
You may watch my webinar at www.ilcellulartherapy.com or call to schedule a consultation (312) 475-1893.
Tags: ACL Injury, arthritis, Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Hip, Interventional Orthopedics, joint replacement, Knee Pain Relief, Mesenchymal Stem Cell, Orthopedic Surgeon, regenerative medicine, stem cell treatment
May 18, 2017
Also known as degenerative joint disease, osteoarthritis is the most common joint disorder, and continues to be the leading cause of impaired quality of life in the United Sates. While OA is defined as the progressive loss of cartilage structure and function; that definition has most recently been expanded to include changes to bone, tissues within and around the joint and changes in alignment.
While trauma, disease, infection, genetics, gout, and neuropathy may lead to secondary osteoarthritis, primary OA is the result of a degeneration that occurs with normal use. This wear and tear of the joint becomes more prevalent with advancing age.
Changes to Cartilage
The progressive loss of cartilage is a process that involves three overlapping stages: cartilage matrix (surroundings) damage, cartilage chondrocyte (cell) response to tissue damage, and decline of chondrocyte synthetic response (ability to maintain its environment)
Changes to Bone
As cartilage degenerates, there is increased exposure of the bone supporting the joint (subchondral bone). With time, the subchondral bone becomes dense (sclerosis) with cyst formation. Cartilage does not regenerate on its own starting about age 40. With time the aborted reparative process may result in osteophyte formation (spurs).
Changes to Periarticular Soft Tissues (in and around the joint)
Synovitis develops (inflammation of the joint lining) because of the release of inflammatory factors by the chondrocytes. A vicious cycle continues with further break down of cartilage followed by thickening of the joint capsule and shortening leading to loss of motion. Muscle undergoes atrophy (shrinkage and weakening) with the relative inactivity of the joint because of pain leading to instability
Changes to Alignment
Abnormal hip-knee-ankle alignment can accelerate structural changes; varus malalignment (bowed leg) increases medial compartment (inner side of the knee) disease fourfold, and valgus (knock knee) malalignment increases lateral (outer) disease twofold. Whether malalignment is associated with development of osteoarthritis or if malalignment is a result of OA is still a subject of debate. However, it has been demonstrated that malalignment can affect more than cartilage because malalignment predis- poses the patient to bone marrow lesions (nonhealing stress fractures).
Treatment of Osteoarthritis
Life style modification, rehabilitation (physical therapy), complementary and alternative therapy, pain relievers, intraarticular injections (cortisone, hyaluronic acid gels), arthroscopic and joint replacement surgery, and now, regenerative intervention.
Regenerative Intervention (an injection, not an incision)
Cellular intervention is what I do. Biologic solutions through cartilage regeneration is the goal of my practice. My stem cell source is the patient’s own bone marrow. Equally important are growth factors; the latter found in bone marrow and in platelets.
To learn more, visit my web site www.sheinkopmd.com
You may watch my webinar www.ilcellulartherapy.com
Then schedule an appointment 312 475 1893
Tags: arthritis, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, Knee Pain Relief, Orthopedic Care, Osteoarthritis, regenerative medicine
May 11, 2017
Last week, my associate attended a continued medical education course held in a venue near the Wisconsin-Illinois border; a site frequently used by the Stem Cell Institute of America to host amniotic fluid marketing seminars. My colleague overheard a conversation between several physical therapists touting the success of amniotic fluid in regenerating cartilage on their patients, “you can see the increased joint space on the x-ray when we see the patient in follow-up”. I have addressed the issue of the absence of viable stem cells in amniotic fluid ad-nauseam (borrowing a recently expressed symptom from the Director of the FBI) but I am continually amazed at how false news when repeated takes on a fantasy of its own. Additionally, my patients frequently ask to repeat the imaging so they might see if the cartilage is growing.
Much of the current research effort pertaining to cartilage is experimental and has to do with the MRI techniques known as T2 mapping and delayed gadolinium enhanced MRI of cartilage (dGEMRIC). In addition to MRI techniques, optical coherence tomography (OCT) may allow arthroscopic evaluation of cartilage by performing microscopic cross-sectional imaging of articular cartilage. In the final analysis, the only present clinical cost effective, non-invasive means of quantitating and qualitating the patient response to an intervention are exactly the parameters I measure in my office; the only comprehensive methodology of its kind in the clinical field of Regenerative Medicine.
When a patient asks me how do I know whether an intervention is a success, I don’t point to an increased joint space on the X-ray as it is not there to be seen. I review patient specific outcomes including pain scores, activity scores, subjective input, and objective measurements and compare the pre-intervention findings with the latest scoring.
In the interval between starting to write this Blog and now, I received an unsolicited update from a patient who had attended the Stem Cell Institute of America seminar. He had asked so many questions during the seminar, the chiropractors running the seminar gave him the PalinGen Flow brochure (their source of amniotic fluid) as my patient had challenged their evidence beyond the speakers’ ability to respond. My patient, who eventually underwent a bone marrow concentrate intervention with my assistance, read the document and learned that PalinGen Flow makes no mention of stem cell content in their literature.
To schedule an appointment call (312) 475-1893
To visit my web site go to www.sheinkopmd.com
To watch my webinar visit www.ilcellulartherapy.com
Tags: arthritis, bone marrow, Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, Interventional Orthopedics, joint replacement, Mesenchymal Stem Cell, Regenerative, regenerative medicine, stem cell treatment
